权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Mechanisms of HBV Functional Cure During Tenofovir-based ART in HIV/HBV Coinfection

HIV/HBV 合并感染中基于替诺福韦的 ART 期间 HBV 功能性治愈的机制

基本信息

批准号：
10684739
负责人：
Michael Jeffrey Vinikoor
金额：
$ 57.57万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-01 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10684739
关键词：
AIDS clinical trial group Adult Affect Antibodies Antigens Biological Markers CD4 Lymphocyte Count Cells Chronic Chronic Hepatitis B Circular DNA Clinical Clinical Research Core Biopsy Country DNA DNA Markers Development Epidemiology Fibrosis Fine needle aspiration biopsy Funding Genetic Transcription Genotype Goals HIV HIV Infections Hepatitis B Hepatitis B Core Antigen Hepatitis B Surface Antigens Hepatitis B Virus Hepatocyte Immune Immune response Immunity Immunologic Factors Immunologics Immunotherapy Individual Intervention Kidney Kinetics Laboratories Liver Measures Mediating Modeling Natural History Outcome Patients Peripheral Phenotype Population Predictive Factor Prospective cohort RNA Research Risk Sampling Serology Surface Surrogate Markers T-Lymphocyte Tenofovir Testing Therapeutic Toxic effect United States National Institutes of Health Viral Viral Genes Virus Work Zambia acute infection analog antiretroviral therapy bone cell type clinical predictors co-infection cohort elastography exhaustion experience genetic signature immune reconstitution immunoregulation inhibitor intrahepatic liver biopsy novel novel marker novel therapeutics predicting response programmed cell death protein 1 reconstitution response single-cell RNA sequencing viral DNA

项目摘要

PROJECT SUMMARY/ABSTRACT Chronic hepatitis B virus (HBV) infection, affecting 240 million worldwide including 5-20% of HIV-infected individuals, results from an inadequate immune response to acute infection and persistence of covalently closed circular DNA (cccDNA) in the host hepatocyte. During nucleos(t)ide analog therapy for chronic HBV, `functional cure', the central therapeutic goal defined by loss of hepatitis B surface antigen (HBsAg) with or without surface antibody development, occurs slowly (~1%/year). There are now a growing number of novel therapies in development to increase HBV functional cure if not achieve virological cure (i.e., elimination of the cccDNA reservoir), including agents to restore HBV-specific immunity. Yet, the immune factors critical to achieving functional cure remain poorly understood because HBsAg loss is usually rare and few studies have assessed intrahepatic immune responses. To guide the use of novel therapies in HIV-HBV coinfection, a better understanding is needed of the impact of HIV and HBV-active antiretroviral therapy (ART) on immune control of HBV. In Zambia, we established a prospective cohort of HIV-HBV coinfected (n=303) and HBV monoinfected (n=63) adults taking tenofovir (TDF)-based therapies. Within this cohort, which has strong local laboratory capacity and access to liver sampling, we documented a strikingly high rate (13.1%) of HBsAg loss among HIV-HBV patients during the first 2 years on TDF-based ART. We now propose to exploit this unique scientific opportunity to investigate HBV functional cure in HIV infection. Our central hypothesis – that in ART- treated HIV-HBV coinfection, robust immune reconstitution unleashes an enhanced HBV functional cure response – will be tested in 3 aims. In Aim 1, using liver fine needle aspirations, we will define the immune milieu in which HIV-HBV patients experience HBsAg loss/reduction during TDF-based therapy. Phenotypic responses and single cell RNA-sequencing signatures of T cells and other immune cell types will be compared by HIV status and CD4 changes during therapy. In Aim 2, we will determine the impact of ART-induced immune reconstitution in HIV-HBV coinfection on the change in peripheral markers of cccDNA transcription including quantitative HBsAg and two novel markers, hepatitis B core-related antigens and HBV RNA. In Aim 3, we will define the clinical predictors of HBV functional cure among HIV-HBV coinfected individuals. This project, which combines translational, clinical, and epidemiological approaches, and leverages an existing NIH- funded cohort, will lead to a better understanding of (a) the impact of HIV on HBV natural history, (b) how immunological therapies might work in HIV-HBV coinfection, and (c) whether novel peripheral cccDNA markers can be used in this population. The proposed research will also advance the broader HBV cure agenda, including the strategy to combine immune modulation with targeted virological interventions to achieve HBV functional cure.

Please try later.

项目成果

期刊论文数量（2）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Hepatitis B in Africa Collaborative Network: cohort profile and analysis of baseline data.

DOI：
10.1017/s095026882300050x
发表时间：
2023-04-03
期刊：
EPIDEMIOLOGY AND INFECTION
影响因子：
4.2
作者：
Riches, Nicholas;Vinikoor, Michael;Guingane, Alice;Johannessen, Asgeir;Lemoine, Maud;Matthews, Philippa;Okeke, Edith;Shimakawa, Yusuke;Sombie, Roger;Stockdale, Alexander;Wandeler, Gilles;Andersson, Monique;Davwar, Pantong;Desalegn, Hailemichael;Duguru, Mary;Fall, Fatou;Maponga, Tongai;Nyam Paul, David;Seydi, Moussa;Sinkala, Edford;Taljaard, Jantjie;Sonderup, Mark;Spearman, C. Wendy
通讯作者：
Spearman, C. Wendy

TREAT-B: Simple Low-Cost Diagnostic Score for When to Treat Hepatitis B.

TREAT-B：关于何时治疗乙型肝炎的简单低成本诊断评分。